In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research
Tag: KPTI
The President & CSO of Karyopharm Therapeutics (NASDAQ: KPTI) is Selling Shares
Yesterday, the President & CSO of Karyopharm Therapeutics (KPTI – Research Report), Sharon Shacham, sold shares of KPTI for $281.6K.
What Did This CEO Just Do with Personal Shares of Karyopharm Therapeutics (NASDAQ: KPTI)?
Yesterday, the CEO of Karyopharm Therapeutics (KPTI – Research Report), Michael Kauffman, sold shares of KPTI for $281.6K. In addition
The EVP, Chief Dev. Officer of Karyopharm Therapeutics (NASDAQ: KPTI) is Selling Shares
Yesterday, the EVP, Chief Dev. Officer of Karyopharm Therapeutics (KPTI – Research Report), Ran Frenkel, sold shares of KPTI for
H.C. Wainwright Thinks Karyopharm Therapeutics’ Stock is Going to Recover
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics (KPTI – Research
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (NASDAQ: KPTI) and Alphatec Holdings (NASDAQ: ATEC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics